In most countries, healthcare decision making is informed by the systematic use of evidence. Health technology assessment (HTA) is the standard policy tool for informing decision makers who must manage the entry and use of pharmaceuticals and other technologies (including complex interventions) within health systems, often through reimbursement and pricing.
The evidence put forward in an HTA dossier, at a minimum, must contain a systematic review of available safety, efficacy and quality of life evidence in the given disease area and, particularly for the UK, a cost-effectiveness analysis.
In this full day course, we take the UK NICE perspective to guide you through the process of building a successful HTA dossier. We will consider who the likely stakeholders will be, the different types of HTA available, the key stages in the HTA process and alternative appraisal routes (e.g. for devices).
This course will provide detailed advice on how best to report the data and analyses that are required for an HTA. This will include sharing recent examples covering several disease areas. The course will also explore the appropriate language and terminology that should be used.
We will also discuss some recent initiatives that have been put forward to comprehensively synthesise good practices in population-based decision-making in recent years, such as those from the ISPOR HTA taskforce, and how these may impact HTA dossier development in the future.
We gebruiken cookies op deze website. Bent u akkoord met het opslaan van cookies voor deze site? JaNeeOns privacybeleid
Privacy & Cookies
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Laatst geüpdatet: 24 juni 2024 door Floor Boekelman
How to Build an HTA Dossier (Online)
Wanneer
Evenement type
In most countries, healthcare decision making is informed by the systematic use of evidence. Health technology assessment (HTA) is the standard policy tool for informing decision makers who must manage the entry and use of pharmaceuticals and other technologies (including complex interventions) within health systems, often through reimbursement and pricing.
The evidence put forward in an HTA dossier, at a minimum, must contain a systematic review of available safety, efficacy and quality of life evidence in the given disease area and, particularly for the UK, a cost-effectiveness analysis.
In this full day course, we take the UK NICE perspective to guide you through the process of building a successful HTA dossier. We will consider who the likely stakeholders will be, the different types of HTA available, the key stages in the HTA process and alternative appraisal routes (e.g. for devices).
This course will provide detailed advice on how best to report the data and analyses that are required for an HTA. This will include sharing recent examples covering several disease areas. The course will also explore the appropriate language and terminology that should be used.
We will also discuss some recent initiatives that have been put forward to comprehensively synthesise good practices in population-based decision-making in recent years, such as those from the ISPOR HTA taskforce, and how these may impact HTA dossier development in the future.
More information.
BMI nieuws